RARE

Ultragenyx Pharmaceutical Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Did you know?

Capital expenditures decreased by 14% from FY24 to FY25.

Current Price

$24.77

+0.32%

GoodMoat Value

$28.14

13.6% undervalued

Profile

Valuation (TTM)

Market Cap$2.39B

P/E-4.16

EV—

P/B—

Shares Out96.48M

P/Sales3.55

Revenue$673.00M

EV/EBITDA—

Ultragenyx Pharmaceutical Inc (RARE) Dividends

Dividend Overview

Dividend Yield

—

Dividend / Share

—

Key Metrics

Market Cap

$2.39B

P/E Ratio

-4.16

Forward P/E

—

EPS

$-5.83

PEG Ratio

0.57

Book Value

$-0.90

Dividend Yield

—

Profit Margin

-85.44%

ROE

—

Dividend History

Dividend Safety

RARE Dividend Analysis

Ultragenyx Pharmaceutical Inc (RARE) dividend analysis including yield, payout history, and sustainability metrics.

P/E ratio: -4.16. Profit margin: -85.44%. Free cash flow: $-472.00M. This page shows Ultragenyx Pharmaceutical Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.

GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Ultragenyx Pharmaceutical Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.